Diversity of Apolipoprotein E genetic polymorphism significance on cardiovascular risk is determined by the presence of Metabolic Syndrome among hypertensive patients

Lipids in Health and Disease

Marcelo Costa Batista¹  Mariana Kuniyoshi²  Silmara de Melo Carmona²  Cassio Jose de Oliveira Rodrigues²  Maria Aparecida Dalboni²  Beata Marie Redublo Quinto²  Mauro Sergio Marrocos²  Andrei Alkmim Teixeira² 

[1] Research and Education Institute, Hospital Israelita Albert Einstein, São Paulo, São Paulo, Brazil;Nephrology Division, Universidade Federal de São Paulo, R. Pedro de Toledo, 781 14o. andar, Vila Clementino, São Paulo, São Paulo CEP 04039-032, Brazil

关键词: Hypertension;    Metabolic syndrome;    Cardiovascular risk;    Polymorphism;    Apolipoprotein E;   

Others  :  1145603
DOI  :  10.1186/1476-511X-13-174

 received in 2014-07-24, accepted in 2014-10-21,  发布年份 2014

【 摘 要 】

Background

Hypertension has a significant relevance as a cardiovascular risk factor. A consistent increase on world’s Metabolic Syndrome (MetS) incidence has been associated with an epidemic cardiovascular risk in different populations. Dislipidemia plays a major role determining the epidemic CV burden attributed to MetS. Apolipoprotein E (ApoE) is involved on cholesterol and triglycerides metabolism regulation. Once ApoE polymorphism may influence lipid metabolism, it is possible that it brings on individual susceptibility consequences for the development of MetS and cardiovascular risk. The objective of the study is to measure the discriminatory power of ApoE polymorphism in determining cardiovascular risk stratification based on the presence MetS in a cohort of hypertensive patients.

Methods

It was enrolled 383 patients, divided in two groups, classified by MetS presence (IDF criteria): Group 1: 266 patients with MetS (MetS +) and Group 2: 117 patients without Mets (MetS -). Patient’s data were collected by clinical evaluation, physical exam, file reviews and laboratory testing. Polymorphic ApoE analysis was performed by PCR amplification. Groups were compared on clinical and laboratory characteristics as well as allele and genotype distribution towards ApoE polymorphism. Mets CVD prevalence was analysed according to E4 allele prevalence.

Results

The results evidenced 184 men (48%), 63,7% whites, 45,1% diabetics and 11,7% of patients were smokers. Mean age was 64,0 ± 12,0 years. When genotypic distribution was analyzed, E3/3 genotype and E3 allele frequencies were more prevalent. Among patients with MetS, we observed an independent association between CVD prevalence and E4 allele frequency (OR 2.42 (1.17- 5.0, p < 0,05)). On the opposite direction, in those without MetS, there was lesser CVD burden in E4 allele carriers (OR 0,14 (0,02-0,75)). These associations remained significant even after confounding factor corrections.

Conclusions

The results presented demonstrate that the association between ApoE gene and CVD may be modulated by the presence of MetS, with an increased CV burden observed among E4 allele carriers with the syndrome. On the opposite way, E4 allele carriers without visceral obesity had lesser prevalence of CVD.

【 授权许可】

   
2014 Teixeira et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P: Heart disease and stroke statistics- 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-e151.
• [2]Thomsen M, Nordestgaard BG: Myocardial infarction and ischemic heart disease in overweight and obesity with and wuthout metabolic syndrome. JAMA Intern Med 2014, 174(1):15-22.
• [3]Olivieri O, Martinelli N, Bassi A, Trabetti E, Girelli D, Pizzolo F, Friso S, Pignatti PF, Corrocher R: ApoE E2/E3/E4 polymorphism, ApoC-II/ApoE ratio and metabolic syndrome. Clin Exp Med 2007, 7:164-172.
• [4]Ferreira DC, Costa TF, Aguiar SLF, Marques ARS, Ramos SA, Gomes KB, Alvarez-Leite JI: Association of apolipoprotein E polymorphisms and metabolic syndrome in subjects with extreme obesity. Clin Chimica Acta 2011, 412:1559-1562.
• [5]Zende PD, Bankar MP, Kamble PS, Momin AA: Apolipoprotein E gene polymorphism and its effects on plasma lipids in arteriosclerosis. J Clin Diagn Res 2013, 7(1):2149-2152.
• [6]Chu AY, Parekh RS, Astor BC, Coresh J, Berthier-Schaad Y, Smith MW, Shuldiner AR, Kao WH: Association of APoE polymorphism with chronic kidney disease in a nationally representative sample: a Third National Health and Nutrition Examination Survey (NHANES III) Genetic Study. BMC Med Gen 2009, 10:108.
• [7]Lee DJ, Kim KM, Kim BT, Kim KN, Joo NS: ApoE polymorphism may determine low-density lipoprotein cholesterol level in association with obesity and metabolic syndrome in postmenopausal Korean women. Yonsei Med J 2011, 52(3):429-434.
• [8]Seshasai RK, Katz R, de Boer IH, Siscovick D, Shlipak MG, Rifkin DE, Sarnak MJ: Apolipoprotein E and kidney function in older adults. Clin Nephrol 2012, 78:174-180.
• [9]Parlier G, Thomas G, Bereziat G, Fontaine JL, Girardet PH: Relation of apolipoprotein E polymorphism to lipid metabolism in obese children. Pediatr Res 1997, 41:682-685.
• [10]Yin YW, Sun QQ, Zhan BB HUAM, Liu HL, Wang Q, Hou ZZ: Association between apoliprotein E gene polymorphism and the risk of coronary artery disease in chinese population: evidence from a meta-analysis of 40 studies. PLos One 2013, 8(6):e66924.
• [11]Eichner JE, Eichner JE, Kuller LH, Orchard TJ: Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol 1993, 71(2):160-165.
• [12]Lehtinen S, Lehtimaki T, Sisto T, Salenius JP, Nikkila M, Jokela H, Koivula T, Ebeling F, Enholm C: Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis 1995, 114(1):83-91.
• [13]Utermann G: Apolipoprotein E, polymorphism in health and disease. Am Heart J 1987, 113(2 Pt 2):433-440.
• [14]Chaudhary R, Likidlilid A, Peerapatdit T, Trsukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C: Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol 2012, 11:36. BioMed Central Full Text
• [15]Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Enholm C, Evans A, Kafatos A, Martins MC, Sans S, Sass C, Visikis S, De Backer G, Siest G: Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis 2000, 152(2):475-488.
• [16]Hixson JE, Apolipoprotein E: polymorphisms affect atherosclerosis in young males. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb 1991, 11(5):1237-1244.
• [17]Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, PAjarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ: Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation 1999, 100(6):608-613.
• [18]Lima LM, Md C, Ferreira CN, Fernandes AP, Neto CP, Garcia JC, Reis HJ, Janka Z, Palotás A, Sousa MD: Atheromatosis extent in coronary artery disease is not correlated with apolipoprotein-E polymorphism and its plasma levels, but associated with cognitive decline. Curr Alzheimer Res 2010, 7(6):556-563.
• [19]WHO Monica Project Principal Investigators: The world health organization monica project (monitoring trends and determinants in cardiovascular disease): a major international coolaboration. J Clin Epidemiol 1988, 41(2):105-114.
• [20]Gerdes LU, Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, Kesaniemi YA, Faergeman O: The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000, 101(12):1366-1371.
• [21]Lahoz C, Schaefer EJ, Cupples LA, Wilson PW, Levy D, Osgood D, Parpos S, Pedro-Bolet J, Daly JA, Ordovas JM: Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 2001, 154(3):529-537.
• [22]Yan MH, Son HJ, Sung JD, Choi YH, Koh KC, Yoo BC, Paik SW: The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepatogastroenterology 2005, 52:1832-1835.
• [23]Kimura H, Suzuki Y, Geiyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M: Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kid Diseas 1998, 31(4):666-673.
• [24]Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E: Apolipoprotein E and progression of chronic kidney disease. JAMA 2005, 293:2892-2899.
• [25]Dallongeville J, Lussier-Cacan S, Davignon J: Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res 1992, 33:447-454.
• [26]Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004, 141:137-147.
• [27]Report A, A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Acute Coronary Syndromes and Coronary Artery Disease Clinical Data Standards): 2013 ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease. J Am Coll Cardiol 2013, 61(9):992-1025.
• [28]American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33(suppl 1):S62-S69.
• [29]Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Sanford Schwartz J, Shero ST, Smith SC Jr, Watson K, Wilson PWF: ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013.